Lung Cancer: Smokers vs. Non-Smokers
- Most lung cancers develop as a result of smoking cigarettes. But there’s a small percentage of lung cancers that develop in “never-smokers.”
- Lung tumors in smokers and tumors in “never-smokers” are a lot different, and a new study released last month highlights this, adding that it’s crucially important that “never-smokers” receive high-quality biopsies and genetic testing on their tumors.
- Research from Washington University found that 78% to 92% of lung cancers in patients who have never smoked may be able to be treated with precision drugs already approved by the U.S. Food and Drug Administration to target specific mutations in a patient's tumor.
Why? Well, researchers at the Washington University School of Medicine in St. Louis recently found that most tumors found in “never-smokers” have a gene mutation also know as a driver mutation and they can be effectively treated with drugs already approved by the U.S. Food and Drug Administration. (And detected with high-quality biopsies and genetic testing.)Read More
"Our study highlights the need to obtain high-quality tumor biopsies for clinical genomic testing in these patients, so we can identify the best targeted therapies for their individual tumors."
What is a Driver Mutation?
These are are specific mistakes in the DNA that fuel tumor growth. The mutations can be blocked with a variety of drugs, according to researchers. And what's more interesting is researchers found that only about half of lung tumors in people who smoke have driver mutations.
There are various different driver mutations: KRAS, EGFR, ALK, ROS1, BRAF, RET, MET and NTRK. And each of these mutations can be treated with targeted drugs that are already approved by the FDA. Here is a list of drugs that are already approved to treat each driver mutation.
- KRAS is treated with sotorasib (brand name: Lumakras)
- EGFR is treated with erlotinib (Tarceva); afatinib (Gilotrif); gefitinib (Iressa); osimertinib (Tagrisso); or dacomitinib (Vizimpro)
- ALK is treated with crizotinib (Xalkori); ceritinib (Zykadia); alectinib (Alecensa); brigatinib (Alunbrig); or lorlatinib (Lorbrena)
- ROS1 is treated with crizotinib (Xalkori); ceritinib (Zykadia); lorlatinib (Lorbrena); or entrectinib (Rozlytrek)
- BRAF is treated with dabrafenib (Tafinlar) or trametinib (Mekinist) this drug is known as a MEK inhibitor, because it attacks the related MEK proteins.
- RET is treated with selpercatinib (Retevmo) or pralsetinib (Gavreto)
- MET is treated with sapmatinib (Tabrecta) or tepotinib (Tepmetko)
- NTRK is treated with larotrectinib (Vitrakvi) or entrectinib (Rozlytrek) a small number of non-small cell lung cancers have changes in one of the NTRK genes.
Lung Cancer: Smokers vs. Non-Smokers
The U.S. Centers for Disease Control and Prevention reports that in the United States, between 10% and 20% of lung cancers (20,000 to 40,000 lung cancers each year) happen in people who have never smoked, or smoked fewer than 100 cigarettes in their lifetime.
For those who do smoke, however, it should be noted that the tobacco in cigarettes is a carcinogen that causes mutations in lung cells and enables the growth of cancer. Several thousand other lung cancer deaths are caused by exposure to secondhand smoke about 7,300 cases each year, according to the CDC.
But there is good news. According to SurvivorNet experts, if you quit smoking, your risk for lung cancer decreases.
"If you're smoking, don't smoke," Dr. Joseph Friedberg, head of thoracic surgery at the University of Maryland School of Medicine, tells SurvivorNet. "You never return down all the way to the (level of) the person who never smoked as far as your risk of lung cancer goes, but it goes down with time."
Researchers analyzed lung tumors from 160 patients with lung adenocarcinoma but no history of tobacco smoking. The "never-smoker" status of a patient was verified by examining the mutation patterns in these patients and comparing them to mutation patterns in lung cancers of patients who had smoked.
Scientists still don't know what causes lung cancer in "never-smokers," but one possibility is that their genes genes they've had since birth contain factors making them more likely to develop a lung tumor. But the researchers found that only 7% of "never-smokers" had mutations present at birth that increase their risk of cancer.
"There appears to be something unique about lung cancer in people who have never smoked," Govindan says. "We didn't find a major role for inherited mutations, and we don't see evidence of large numbers of mutations, which would suggest exposure to secondhand smoke."
"About 60% of these tumors are found in females and 40% in males. Cancer in general is more common among men, but lung cancer in never-smokers, for some unexplained reasons, is more common among women. It is possible additional genes are involved with predispositions to cancers of this kind, and we just don't know what those are yet."